Ajalorin

Ajalorin Dosage/Direction for Use

desloratadine

Manufacturer:

AJ Research & Pharma

Distributor:

AJ Research & Pharma
Full Prescribing Info
Dosage/Direction for Use
Ajalorin 2.5 mg Orodispersible Tablet: Adults and adolescents 12 years of age and over: The recommended dose of Desloratadine 2.5 mg orodispersible tablets is two 2.5 mg orodispersible tablets placed in the mouth once a day.
Paediatric population: Children 6 to 11 years of age: the recommended dose of desloratadine is one 2.5 mg orodispersible tablet placed in mouth once a day.
The safety and efficacy of desloratadine 2.5 mg orodispersible tablets in children below the age of 6 years have not been established. No data are available.
There is limited clinical trial efficacy experience with the use of desloratadine in children 6 through 11 years of age.
There is limited clinical trial efficacy experience with the use of desloratadine in adolescents 12 through 17 years of age.
Intermittent allergic rhinitis (presence of symptoms for less than 4 days per week or for less than 4 weeks) should be managed in accordance with the evaluation of patient's disease history and the treatment could be discontinued after symptoms are resolved and reinitiated upon their reappearance. In persistent allergic rhinitis (presence of symptoms for 4 days or more per week and for more than 4 weeks), continued treatment may be proposed to the patients during the allergen exposure periods.
Ajalorin 5 mg Orodispersible Tablet: Adults and adolescents (12 years of age and over): The recommended dose of Desloratadine 5 mg orodispersible tablet is one 5 mg orodispersible tablets placed in the mouth once a day.
Intermittent allergic rhinitis (presence of symptoms for less than 4 days per week or for less than 4 weeks) should be managed in accordance with the evaluation of patient's disease history and the treatment could be discontinued after symptoms are resolved and reinitiated upon their reappearance. In persistent allergic rhinitis (presence of symptoms for 4 days or more per week and for more than 4 weeks), continued treatment may be proposed to the patients during the allergen exposure periods.
Paediatric population: There is limited clinical trial efficacy experience with the use of desloratadine in adolescents 12 through 17 years of age.
The safety and efficacy of desloratadine 5 mg orodispersible tablets in children below the age of 12 years have not been established. No data are available.
Method of Administration: Oral use.
The dose can be taken with or without food.
Immediately before use, the blister must be carefully peeled open and the dose of orodispersible tablet removed without crushing it. The dose of orodispersible tablet is placed in the mouth where it will disperse immediately. Water or other liquid is not needed to swallow the dose. The dose must be taken as soon as the blister has been opened.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in